Literature DB >> 21752775

Understanding the landscape of MTM programs for Medicare. Part D: Results from a study for the Centers for Medicare & Medicaid services.

Sarah J Shoemaker1, Andrea Hassol.   

Abstract

OBJECTIVES: To describe the features of medication therapy management (MTM) programs, including eligibility criteria, enrollment, services, and reimbursement, and to describe the criteria used to evaluate MTM programs and assess the evidence of relevance to Medicare.
DESIGN: Descriptive, exploratory, nonexperimental study.
SETTING: United States between July 2007 and June 2008. PARTICIPANTS: 60 key informants from 46 different organizations and case studies with 28 representatives from four MTM programs. INTERVENTION: Literature review, key informant interviews, and evaluation of case studies. MAIN OUTCOME MEASURES: MTM program features and evidence of effectiveness.
RESULTS: MTM programs used a variety of practice models. Medicare MTM programs used different eligibility criteria than MTM programs sponsored by Medicaid or other payers. MTM programs that required patients to opt-in had less success in enrolling participants than those using opt-out. Most MTM programs conducted annual medication reviews. Most non-Medicare MTM programs provided face-to-face interventions, whereas Medicare MTM programs relied more on telephone or mail; no research tested the effectiveness of different modes. Almost all MTM programs used pharmacists to provide services. Little research on Medicare MTM programs was available. Costs were commonly measured in the MTM literature, although results were inconsistent. A few studies demonstrated significant improvements in intermediate outcomes (e.g., low-density lipoprotein cholesterol), while less studies demonstrated an impact on serious sequelae (e.g., emergency department visits).
CONCLUSION: Medicare MTM programs were still evolving when this study was conducted, and we found limited evidence to determine which beneficiaries would benefit most from MTM, which features achieved the desired outcomes, and which outcomes should be measured to compare MTM program performance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21752775     DOI: 10.1331/JAPhA.2011.10210

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  4 in total

1.  Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.

Authors:  Amy Barton Pai; Katie E Cardone; Harold J Manley; Wendy L St Peter; Rachel Shaffer; Michael Somers; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

2.  Twelve-month prospective randomized study of pharmacists utilizing point-of-care testing for metabolic syndrome and related conditions in subjects prescribed antipsychotics.

Authors:  Mark E Schneiderhan; Sara M Shuster; Cynthia S Davey
Journal:  Prim Care Companion CNS Disord       Date:  2014-10-30

3.  Racial and ethnic disparities in meeting MTM eligibility criteria among patients with asthma.

Authors:  Degan Lu; Yanru Qiao; Karen C Johnson; Junling Wang
Journal:  J Asthma       Date:  2016-09-27       Impact factor: 2.515

4.  Pharmaceutical care in Brazil's primary health care.

Authors:  Patricia Sodré Araújo; Ediná Alves Costa; Augusto Afonso Guerra; Francisco de Assis Acurcio; Ione Aquemi Guibu; Juliana Álvares; Karen Sarmento Costa; Margô Gomes de Oliveira Karnikowski; Orlando Mario Soeiro; Silvana Nair Leite
Journal:  Rev Saude Publica       Date:  2017-11-13       Impact factor: 2.106

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.